Related Experiment Video
Updated: Sep 4, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Moving the Needle on Precision Medicine in Pancreatic Cancer
Grainne M O'Kane1,2, Maeve A Lowery1
1Trinity St James Cancer Institute, Dublin, Ireland.
Abstract:
The management of pancreatic ductal adenocarcinoma (PDAC) has posed a considerable challenge for decades, with incidence and mortality rates almost mirroring each other. Despite this, a deeper understanding of the complex biology inherent to PDAC has provided a roadmap for a more precise approach to treatment. PDAC deficient in homologous recombination repair and mismatch repair is a subgroup that should be identified in the clinic for a targeted approach. In addition, KRAS wild-type PDAC, occurring in approximately 10% of patients, is enriched in highly actionable alterations including fusions, underscoring the importance of integrative germline and somatic sequencing. Comprehensive sequencing efforts over the past decade have documented genomic- and transcriptomic-based classifiers, with the latter emerging as two main subtypes: the classical and basal-like, which are now being evaluated in clinical trials. Together with promising, innovative strategies to target KRAS mutations and their pleotropic effects, a new era of precision medicine in PDAC is on the horizon.
Insights
Pancreatic cancer management is challenging, but understanding its biology reveals targeted treatment strategies. Identifying specific genetic profiles like homologous recombination deficiency and KRAS wild-type status guides precision medicine for pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant clinical challenges with high mortality rates.
- Advances in understanding PDAC's complex biology are paving the way for more precise therapeutic strategies.
- Subgroups with specific DNA repair deficiencies (homologous recombination repair and mismatch repair) require targeted clinical identification.
Purpose of the Study:
- To highlight the importance of identifying specific molecular subtypes within PDAC for targeted treatment.
- To emphasize the clinical utility of integrative germline and somatic sequencing for actionable alterations.
- To discuss emerging genomic and transcriptomic classifiers for PDAC treatment stratification.
Main Methods:
- Review of comprehensive genomic and transcriptomic sequencing data from PDAC patients over the past decade.
- Analysis of PDAC subgroups based on DNA repair deficiencies (homologous recombination repair, mismatch repair).
- Evaluation of KRAS wild-type PDAC for actionable genetic alterations, including fusions.
Main Results:
- Identification of PDAC subgroups benefiting from targeted therapies based on DNA repair status.
- KRAS wild-type PDAC (approx. 10% of cases) shows enrichment of actionable alterations, necessitating integrative sequencing.
- Genomic and transcriptomic classifiers, including classical and basal-like subtypes, are emerging and under clinical evaluation.
Conclusions:
- Precision medicine approaches are revolutionizing PDAC management.
- Targeting specific molecular pathways, including KRAS mutations, offers new therapeutic avenues.
- A new era of personalized treatment for pancreatic ductal adenocarcinoma is approaching.
